Free Fatty Acid Induced Insulin Resistance (FFAIR)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims to explore time-dependent effects of lipid infusion an intramyocellular lipid metabolites and the induction of impaired insulin signaling.
| Condition | Intervention |
|---|---|
|
Insulin Resistance |
Dietary Supplement: Lipovenös lipid infusion |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Assessment of the Time Course of Lipid Induced Insulin Resistance |
- intramyocellular lipid metabolites [ Time Frame: after 4 hours lipid infusion ] [ Designated as safety issue: No ]Muscle biopsies are taken before, after 2.5 and 4 hours of lipid infusion
- insulin resistance of glucose uptake and mitochondrial function [ Time Frame: after 4 hours lipid infusion ] [ Designated as safety issue: No ]Mitochondrial function will bes assessed from muscle biopsy samples taken after 4 hours, insulin sensitivity will be assessed from hyperinsulinemic-euglycemic clamps following 4 hours lipid infusion
Biospecimen Retention: Samples With DNA
muscle biopsies
| Estimated Enrollment: | 15 |
| Study Start Date: | March 2010 |
| Estimated Study Completion Date: | April 2011 |
| Estimated Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
lipid infusion
healthy lean humans before and after lipid infusion
|
Dietary Supplement: Lipovenös lipid infusion
Lipid enriched infusions will be applied for 2-6 hours.
Other Name: soy oil
|
Detailed Description:
Increased availability of free fatty acids impairs glucose disposal in young healthy humans. Patients with type 2 diabetes have reduced whole body glucose disposal, increased ectopic lipid deposition in skeletal muscle and the liver and impaired mitochondrial function. Recent studies suggest that lipid metabolites such as diacylglycerol (DAG), ceramides and long-chain acyl-coA represent the active mediators inducing insulin resistance. Possible targets are DAG-sensitive Proteinkinase C (PKC θ, PKC ε) which inhibit the insulin signaling cascade and ceramides which interfere with the insulin signaling cascade at Proteinkinase B/AKT. Prior studies raised controvesial evidence, thus, it is yet unclear, whether DAG or ceramides are the primary agents inducig lipid-induced insulin resistance. Therefore, the current study aims to explore the time course of the appearance of intramyocellular lipid compunds during lipid infusion in parallel assessing markers of impaired insulin action.
Eligibility| Ages Eligible for Study: | 20 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Healthy, lean non-diabetic humans
Inclusion Criteria:
- non-diabetic (OGTT), no family history of diabetes, BMI<30 kg/m2, age: 20-55 years, no medication,
Exclusion Criteria:
- acute illness within the last 2 weeks, autoimmune diseases, renal insufficiency (creatinine> 1.5 mg/dl), cardiovascular diseases, anemia (Hb< 12g/l), donation of blood within the last 4 weeks before the study, thyroid diseases, pregnancy, smoking, night-shift working (disturbed circadian rhythm), defective coagulation or wound healing, cancer, allergy against soja products
Contacts and Locations| Contact: Michael Roden, MD | 00492113382 ext 201 | michael.roden@ddz.uni-duesseldorf.de |
| Germany | |
| German Diabetes Center | Recruiting |
| Duesseldorf, NRW, Germany, 40225 | |
| Contact: Michael Roden, MD 00492113382 ext 201 michael.roden@ddz.uni-duesseldorf.de | |
| Principal Investigator: Michael Roden, MD | |
| Principal Investigator: | Michael Roden, Prof | German Diabetes Center |
More Information
No publications provided
| Responsible Party: | M. Roden, Professor, MD, German Diabetes Center, Düsseldorf |
| ClinicalTrials.gov Identifier: | NCT01229059 History of Changes |
| Other Study ID Numbers: | FFAIR |
| Study First Received: | March 20, 2010 |
| Last Updated: | October 26, 2010 |
| Health Authority: | Germany: Ethics Commission |
Keywords provided by German Diabetes Center:
|
FFA insulin resistance mitochondria |
Additional relevant MeSH terms:
|
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
Insulin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013